David Hsia, Ph.D. Joins Kinex Pharmaceuticals' Board of Directors

    BUFFALO, N.Y., Sept. 15 /PRNewswire/ -- Kinex Pharmaceuticals announced
 that David Hsia, Ph.D. has been appointed to the Company's Board of
 Directors.
 
     Dr. Hsia is a pharmaceutical veteran. He is a co-founder of Watson
 Pharmaceuticals, a publicly traded company listed in New York Stock
 Exchange (ticker: WPI). He was formerly Senior Vice President, Scientific
 Affairs of Watson Pharmaceuticals before his retirement. He has been
 involved in the development of various pharmaceutical formulations for over
 twenty years. Dr. Hsia received a Ph.D. in Industrial and Physical Pharmacy
 from Purdue University in 1975.
 
     "Dr. Hsia is well known for his expertise in pharmaceutical development
 in our industry," commented Dr. Allen Barnett, Chief Executive Officer of
 Kinex Pharmaceuticals. "As the Company moves forward, we look forward to
 leveraging the full breadth of David's expertise as a Board member to
 assist us in developing our new drug candidates," Commented Dr. Johnson
 Lau, Executive Chairman of the Board.
 
     "I am delighted to have a chance to work with the team at Kinex. The
 company's pipeline is very strong and I am glad to have this opportunity to
 assist to further advance their product pipeline," commented Dr. Hsia.
 
     About Kinex Pharmaceuticals
 
     Kinex is a drug discovery and development company that is focused on
 the use of its platform technology and compound libraries to identify and
 develop peptide-competitive kinase inhibitors. The Company's clinical
 compound KX2-391 is a selective Src kinase inhibitor that is currently in
 Phase 1 trials for oncology. Kinex's pipeline is focused on selective
 inhibitors for kinase targets that are important in oncology and
 inflammation and immunology. The Company is located in the New York State
 Center of Excellence in Bioinformatics and Life Sciences, on the Buffalo
 Niagara Medical Campus in Buffalo, New York.
 
 
 

SOURCE Kinex Pharmaceuticals